Ovid Therapeutics, Inc.

Industry

  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Vaccines
See more in Biomedtracker

Latest on Ovid Therapeutics, Inc.

In Vivo

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By Jo Shorthouse

Meg Alexander, president and chief operating officer of Ovid Therapeutics, brings extensive industry experience to her role at the New York-based biotech, a company focused on developing medicines for

Scrip

Deal Watch: Oak Hill Picks Up Where Roche Left Off In Angelman Syndrome

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Oak Hill Licenses Roche’s Rugonersen,

Scrip

Biotech Leaders Fear FDA Disruption Is Causing Delays

 
• By Jessica Merrill

A letter to US Senate Health, Education, Labor and Pensions (HELP) committee chairman Bill Cassidy, R-LA, from more than 200 biotech leaders, investors and patient advocates cites cases of disruptions

In Vivo

In Vivo’s 2025 Rising Leaders

 
• By Jo Shorthouse

Included for 2025 are investors, CEOs of small and mid-sized companies, rising employees in larger businesses, and individuals spearheading unique health initiatives worldwide. The 30 individuals list